As the coronavirus continues to evolve, a key finding from the World Health Organization’s data remains critical: three doses of a COVID-19 vaccine continue to prevent severe illness from Omicron and its subvariants. This protection against hospitalization and death persists even as the virus mutates into new forms.
The Omicron variant was first reported to the WHO on November 24, 2021, by South Africa’s Network for Genomics Surveillance. It had already been detected in Botswana. Since then, Omicron has become the dominant strain of SARS-CoV-2 globally, giving rise to a family of subvariants including BA.1, BA.2, BA.3, BA.4, and BA.5.
By October 2022, two additional subvariants emerged: BQ.1 and BQ.1.1, both descended from BA.5. Each new subvariant demonstrates increased transmissibility.
BA.4 and BA.5 are more infectious than earlier strains and can infect individuals who have received three vaccine doses. However, the vaccines continue to work where it matters most: preventing critical illness and death in those who are fully vaccinated. The pattern is clear: Omicron and its descendants are more adept at evading antibodies, but they are not more capable of causing severe disease in people with a complete vaccine schedule.
This distinction is important. Public health messages sometimes focus on breakthrough infections, which are real, but this can create the impression that vaccines are failing.
The data shows they are not. Three doses train the immune system to recognize the virus through multiple mechanisms. Even when antibody levels wane, T-cells and memory B-cells mount a defense.
This immune response does not prevent every infection, but it does prevent most severe outcomes. The WHO data explicitly states that three doses still provide protection against severe disease and hospitalization from Omicron and all its subvariants.
The emergence of BQ.1 and BQ.1.1 adds complexity. As offshoots of BA.5, the most transmissible version of the virus to date, they carry more mutations that could help them evade immune responses. Genomic surveillance networks are monitoring these developments closely, tracking which mutations appear and how quickly they spread. This information guides decisions about boosters and public health measures.
Omicron outcompeted earlier variants like Delta and took over global circulation. This dominance has consequences for healthcare systems.
A variant that infects more people, even if it causes milder illness on average, still fills hospitals when case numbers are high. Vulnerable populations—the elderly, the immunocompromised, and the unvaccinated—bear the heaviest burden. The WHO has not declared Omicron a variant of concern without reason.
Its ability to adapt is remarkable. BA.4 and BA.5 emerged, followed by BQ.1 and BQ.1.1.
More subvariants will follow. The virus is not done evolving. But the protection from three doses is not done working either.
That is the counterweight: the virus changes, but the vaccines hold the line on severe disease. It is not a perfect defense, but it is a good one.
Global health strategies must account for both realities. Omicron will keep mutating. Vaccines will keep preventing the worst outcomes.
The challenge is to maintain surveillance, continue booster rollouts, and inform the public without causing panic. The facts are straightforward: the virus adapts, and the vaccines protect.
Both statements are true at the same time.
